Search research articles
Contact Us
Filters
Showing results (151-160 of 367) with videos related to
Page
of 37
Sort By:
EJNMMI Research
|
February 9, 2019
Repeatability of [<sup>18</sup>F]FDG PET/CT total metabolic active tumour volume and total tumour burden in NSCLC patients
Guilherme D Kolinger, David Vállez García, Gerbrand M Kramer, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
January 19, 2016
A Population-Based Analysis of Application of WHO Nomenclature in Pathology Reports of Pulmonary Neuroendocrine Tumors
Jules L Derks, Robert Jan van Suylen, Erik Thunnissen, et al.
Journal of Proteomics
|
February 3, 2019
Proteome analysis of non-small cell lung cancer cell line secretomes and patient sputum reveals biofluid biomarker candidates for cisplatin response prediction
Franziska Böttger, Tieneke B Schaaij-Visser, Inge de Reus, et al.
Molecular Cancer Therapeutics
|
February 18, 2010
Association of polymorphisms in AKT1 and EGFR with clinical outcome and toxicity in non-small cell lung cancer patients treated with gefitinib
Elisa Giovannetti, Paolo A Zucali, Godefridus J Peters, et al.
EJNMMI Research
|
April 9, 2015
A comparative PET imaging study with the reversible and irreversible EGFR tyrosine kinase inhibitors [(11)C]erlotinib and [(18)F]afatinib in lung cancer-bearing mice
Paul Slobbe, Albert D Windhorst, Marijke Stigter-van Walsum, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
June 7, 2013
Pharmacokinetic analysis of [18F]FAZA in non-small cell lung cancer patients
Eline E Verwer, Floris H P van Velden, Idris Bahce, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
October 22, 2008
Reproducibility of quantitative 18F-3'-deoxy-3'-fluorothymidine measurements using positron emission tomography
Adrianus J de Langen, Bianca Klabbers, Mark Lubberink, et al.
Lung Cancer (Amsterdam, Netherlands)
|
April 9, 2021
Identifying advanced stage NSCLC patients who benefit from afatinib therapy using <sup>18</sup>F-afatinib PET/CT imaging
Eveline A van de Stadt, Maqsood Yaqub, Adriaan A Lammertsma, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
June 28, 2014
Assessment of simplified methods to measure 18F-FLT uptake changes in EGFR-mutated non-small cell lung cancer patients undergoing EGFR tyrosine kinase inhibitor treatment
Virginie Frings, Maqsood Yaqub, Lieke L Hoyng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 1, 2024
Combining Genomic Biomarkers to Guide Immunotherapy in Non-Small Cell Lung Cancer
Joris van de Haar, Joanne M Mankor, Karlijn Hummelink, et al.
Page
of 37
Search research articles
Search
Showing results (151-160 of 367) with videos related to
Sort By:
Page
of 37
EJNMMI Research
|
February 9, 2019
Repeatability of [<sup>18</sup>F]FDG PET/CT total metabolic active tumour volume and total tumour burden in NSCLC patients
Guilherme D Kolinger, David Vállez García, Gerbrand M Kramer, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
January 19, 2016
A Population-Based Analysis of Application of WHO Nomenclature in Pathology Reports of Pulmonary Neuroendocrine Tumors
Jules L Derks, Robert Jan van Suylen, Erik Thunnissen, et al.
Journal of Proteomics
|
February 3, 2019
Proteome analysis of non-small cell lung cancer cell line secretomes and patient sputum reveals biofluid biomarker candidates for cisplatin response prediction
Franziska Böttger, Tieneke B Schaaij-Visser, Inge de Reus, et al.
Molecular Cancer Therapeutics
|
February 18, 2010
Association of polymorphisms in AKT1 and EGFR with clinical outcome and toxicity in non-small cell lung cancer patients treated with gefitinib
Elisa Giovannetti, Paolo A Zucali, Godefridus J Peters, et al.
EJNMMI Research
|
April 9, 2015
A comparative PET imaging study with the reversible and irreversible EGFR tyrosine kinase inhibitors [(11)C]erlotinib and [(18)F]afatinib in lung cancer-bearing mice
Paul Slobbe, Albert D Windhorst, Marijke Stigter-van Walsum, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
June 7, 2013
Pharmacokinetic analysis of [18F]FAZA in non-small cell lung cancer patients
Eline E Verwer, Floris H P van Velden, Idris Bahce, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
October 22, 2008
Reproducibility of quantitative 18F-3'-deoxy-3'-fluorothymidine measurements using positron emission tomography
Adrianus J de Langen, Bianca Klabbers, Mark Lubberink, et al.
Lung Cancer (Amsterdam, Netherlands)
|
April 9, 2021
Identifying advanced stage NSCLC patients who benefit from afatinib therapy using <sup>18</sup>F-afatinib PET/CT imaging
Eveline A van de Stadt, Maqsood Yaqub, Adriaan A Lammertsma, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
June 28, 2014
Assessment of simplified methods to measure 18F-FLT uptake changes in EGFR-mutated non-small cell lung cancer patients undergoing EGFR tyrosine kinase inhibitor treatment
Virginie Frings, Maqsood Yaqub, Lieke L Hoyng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 1, 2024
Combining Genomic Biomarkers to Guide Immunotherapy in Non-Small Cell Lung Cancer
Joris van de Haar, Joanne M Mankor, Karlijn Hummelink, et al.
Page
of 37